Palisade Bio reports Phase 1a/1b PALI-2108 data showing rapid improvement in moderate-to-severe ulcerative colitis
PALI•Palisade Bio reported early PALI-2108 study results showing rapid symptom improvement in ulcerative colitis, with biopsy findings consistent with reduced intestinal inflammation. The company said pharmacokinetic results supported once-daily dosing and that Phase 2 trials are ongoing, including ASCENTRA-UC, which is enrolling about 204 patients.
1. Early study findings
Palisade Bio released clinical and translational results for PALI-2108, which it had presented in five posters at ACG 2026. Small early-stage ulcerative colitis studies showed rapid symptom improvement, with biopsy findings consistent with reduced intestinal inflammation.
2. Crohn’s and Phase 2 updates
A separate early Crohn’s cohort showed early endoscopic improvement and biomarker shifts suggesting anti-inflammatory activity; fibrosis reversal was not established. Pharmacokinetic work supported once-daily dosing, and program updates supported ongoing Phase 2 trials in ulcerative colitis and Crohn’s disease, including ASCENTRA-UC, which is enrolling about 204 patients.
